TABLE 2.
Detrimental effects of statins on PD.
| Study type | Findings | Ref. |
|---|---|---|
| A retrospective study | The use of statins (especially lipophilics) was associated with a higher risk of PD. | Liu et al. 63 |
| A prospective study | Short‐term effects of statins may associate with an increased risk for the development of PD. | Jeong et al. 65 |
| A clinical trial study | Simvastatin deteriorates motor symptoms in PD patients. | Stevens et al. 66 |
| An experimental study | Atorvastatin increases the severity of MPTP‐induced PD in mice | Kreisler et al. 67 |
| An experimental study | Statins may initially exacerbate motor dysfunction in PD via the reduction of expression of dopamine transporters. | Fukui et al. 71 |
| A prospective study | Lipophilic statins lead to a more detrimental effect on PD neuropathology. | Jeong et al. 27 |
| A case–control study | Lipophilic but not hydrophilic statins for more than 12 months were associated with a higher risk for the development of PD. | Kim et al. 74 |
| A prospective study | Hydrophilic statins are linked with the rapid progression of PD neuropathology. | Lewis et al. 75 |